Article
Differing response to antipsychotic therapy in schizophrenia: pharmacogenomic aspects
2004-03-31
Abstract excerpt
Treatment-resistance in schizophrenia remains a public health problem: about 20% to 30% of patients do not respond to antipsychotic therapy. Clozapine has been shown to be effective in about one-third of patients, but the medical risks and weekly blood tests limit its broad application. While the heterogeneity of the disease and the duration of untreated psychosis are important, pharmacogenomic aspects must also b...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 293e7872-81d0-5bbf-9d0d-00ddc806d47a
- DOI
- 10.31887/dcns.2004.6.1/mackenheil